東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

HuR regulates Poly ADP Ribose Glycoh...

Chand, Saswati.

FindBook

Google Book

Amazon

博客來

HuR regulates Poly ADP Ribose Glycohydrolase: Implications for PARP inhibitor efficacy in pancreatic ductal adenocarcinoma cells.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	HuR regulates Poly ADP Ribose Glycohydrolase: Implications for PARP inhibitor efficacy in pancreatic ductal adenocarcinoma cells./
作者:	Chand, Saswati.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2017,
面頁冊數:	158 p.
附註:	Source: Dissertation Abstracts International, Volume: 78-10(E), Section: B.
Contained By:	Dissertation Abstracts International78-10B(E).
標題:	Molecular biology. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10284920
ISBN:	9781369810844

HuR regulates Poly ADP Ribose Glycohydrolase: Implications for PARP inhibitor efficacy in pancreatic ductal adenocarcinoma cells.
Chand, Saswati.

HuR regulates Poly ADP Ribose Glycohydrolase: Implications for PARP inhibitor efficacy in pancreatic ductal adenocarcinoma cells. - Ann Arbor : ProQuest Dissertations & Theses, 2017 - 158 p.

Source: Dissertation Abstracts International, Volume: 78-10(E), Section: B.

Thesis (Ph.D.)--Thomas Jefferson University, 2017.

Overcoming drug resistance requires identification of redundant survival signals. Even in the best case scenario of personalized medicine wherein cancer- specific genomic alterations are treated with molecular targeted therapeutics, increasing resistance predicates concurrent identification of compensatory mechanisms. For a lethal malignancy with limited treatment options such as pancreatic ductal adenocarcinoma ( PDA), the development and clinical implementation of a novel targeted strategy i.e. PARP inhibitors was a major breakthrough. However, PARPi have not progressed as a frontline therapy for PDA patients despite being in the clinical trials pipeline for over a decade now. Identifying and combating de novo and acquired PARPi resistance mechanisms is a critical medical goal in oncology, and the focus of this study. Attempts to target the most frequent mutations in PDA patient samples, including KRAS (86%), TP53 (68%), CDKN2A (21%), SMAD4 (21%) and EGFR (7%) identified through multiple next-generation sequencing studies haven't yielded any considerable success. However, over 10% of PDA patients are associated with germline or sporadic loss of DNA repair and genome maintenance genes, specifically BRCA1 and BRCA2, which compromises repair of damaged DNA resulting in increased chromosomal instability (CIN). Paradoxically, while CIN promotes tumorigenesis, these genetic mutations become the tumor cells' "Achilles heel". These DDR- defective cells rely heavily on an alternative DNA repair pathway dictated by PARP1, and thus are particularly susceptible to PARP inhibitors and intra-strand crosslinkers such as mitomycin C, cisplatin, etc. Therefore, DNA damage repair (DDR), one of twelve core signaling pathways dysregulated in PDA, has provided a promising approach for treating selective patients with DNA repair-deficient tumors. Unfortunately, there is an unmet demand to understand how initially responsive patients develop resistance to PARPi. While genomic and proteomic alterations, such as BRCA reversion mutation or upregulation of a PARPi efflux pump respectively, have been widely explored as PARPi resistance mechanisms, rapid reprogramming of the RNA expression signature in response to PARPi exposure has been largely ignored.

ISBN: 9781369810844Subjects--Topical Terms:

517296
Molecular biology.

HuR regulates Poly ADP Ribose Glycohydrolase: Implications for PARP inhibitor efficacy in pancreatic ductal adenocarcinoma cells.
LDR:04371nmm a2200313 4500 001 2124093
005 20171023101708.5
008 180830s2017 ||||||||||||||||| ||eng d
020 $a 9781369810844
035 $a (MiAaPQ)AAI10284920
035 $a AAI10284920
040 $a MiAaPQ $c MiAaPQ
100 1 $a Chand, Saswati. $3 3286069
245 1 0 $a HuR regulates Poly ADP Ribose Glycohydrolase: Implications for PARP inhibitor efficacy in pancreatic ductal adenocarcinoma cells.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2017
300 $a 158 p.
500 $a Source: Dissertation Abstracts International, Volume: 78-10(E), Section: B.
500 $a Adviser: Jonathan R. Brody.
502 $a Thesis (Ph.D.)--Thomas Jefferson University, 2017.
520 $a Overcoming drug resistance requires identification of redundant survival signals. Even in the best case scenario of personalized medicine wherein cancer- specific genomic alterations are treated with molecular targeted therapeutics, increasing resistance predicates concurrent identification of compensatory mechanisms. For a lethal malignancy with limited treatment options such as pancreatic ductal adenocarcinoma ( PDA), the development and clinical implementation of a novel targeted strategy i.e. PARP inhibitors was a major breakthrough. However, PARPi have not progressed as a frontline therapy for PDA patients despite being in the clinical trials pipeline for over a decade now. Identifying and combating de novo and acquired PARPi resistance mechanisms is a critical medical goal in oncology, and the focus of this study. Attempts to target the most frequent mutations in PDA patient samples, including KRAS (86%), TP53 (68%), CDKN2A (21%), SMAD4 (21%) and EGFR (7%) identified through multiple next-generation sequencing studies haven't yielded any considerable success. However, over 10% of PDA patients are associated with germline or sporadic loss of DNA repair and genome maintenance genes, specifically BRCA1 and BRCA2, which compromises repair of damaged DNA resulting in increased chromosomal instability (CIN). Paradoxically, while CIN promotes tumorigenesis, these genetic mutations become the tumor cells' "Achilles heel". These DDR- defective cells rely heavily on an alternative DNA repair pathway dictated by PARP1, and thus are particularly susceptible to PARP inhibitors and intra-strand crosslinkers such as mitomycin C, cisplatin, etc. Therefore, DNA damage repair (DDR), one of twelve core signaling pathways dysregulated in PDA, has provided a promising approach for treating selective patients with DNA repair-deficient tumors. Unfortunately, there is an unmet demand to understand how initially responsive patients develop resistance to PARPi. While genomic and proteomic alterations, such as BRCA reversion mutation or upregulation of a PARPi efflux pump respectively, have been widely explored as PARPi resistance mechanisms, rapid reprogramming of the RNA expression signature in response to PARPi exposure has been largely ignored.
520 $a This is the first study to demonstrate that post-transcriptional gene regulation (PTGR) by an RNA- binding protein HuR upregulates expression of a novel resistance gene Poly-ADP Ribose Glycohydrolase (PARG) which supports DNA damage response and facilitates PARPi resistance. We have previously shown that HuR-mediated transcriptomic rewiring causes PDA cells to reprogram core cellular processes and enhance expression of several pro-survival factors such as DCK, WEE1 and PIM1 which, in turn, support acute chemoresistance and survival of PDA cells in a harsh tumor microenvironment. The ultimate clinical goal of this study relates to 1) optimizing and extending a proven synthetic lethal therapeutic strategy to all pancreatic cancer patients, regardless of their DNA-repair status, 2) recognizing PARG as a more suitable target over PARP1 due to its ability to be acutely induced in response to drug exposure and 3) inhibiting PARG and/or HuR as an effective therapeutic strategy to improve efficacy of not only PARP inhibitor therapy but other chemotherapy regimens in pancreatic cancer.
590 $a School code: 0272.
650 4 $a Molecular biology. $3 517296
650 4 $a Biochemistry. $3 518028
650 4 $a Pharmacology. $3 634543
690 $a 0307
690 $a 0487
690 $a 0419
710 2 $a Thomas Jefferson University. $b Biochemistry and Molecular Biology. $3 3286070
773 0 $t Dissertation Abstracts International $g 78-10B(E).
790 $a 0272
791 $a Ph.D.
792 $a 2017
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10284920